Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

Abstract: The present invention provides a medicament comprising a gene encoding an angiogenic cytokine for the treatment of acute myocardial infarction (AMI), idiopathic cardiomyopathy (ICM), dilated cardiomyopathy (DCM) or heart failure, to be given in combination with ventricular assist device (VAD).

Abstract: The present invention provides introduction of NF-?B decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-?B decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor ?, interleukin 1? and intracellular adhesion molecule 1 messenger RNAs. Terminal deoxynucleotidyl transferase-mediated deoxyuridine nick-end labeling staining and immunohistochemistry using microtubule-associated protein 2 demonstrated that transfected NF-?B decoy oligodeoxynucleotide significantly attenuated neuronal damage seven days after global brain ischemia. Therapeutic transfection of NF-?B decoy oligodeoxynucleotide during brain ischemia may be effective for attenuation of neuronal damage, suggesting a strategy for protecting the cerebrum from global ischemia.

Abstract: Decellularization of tissue by means of an amphipathic solvent a well-established practice. However, situations exist where the provision of enhanced decellularization is preferred. There is a demand for treating methods for coping with such situations. Thus, it is intended to provide a method for enhancing decellularization. The method comprises not only the immersing of a tissue in a solution containing an amphiphilic molecule in non-micellar form (for example, 1,2-epoxide polymer) but also performing a radical reaction (for example, treatment selected from the group consisting of exposure to gamma-ray irradiation, ultraviolet irradiation, a free radical supply source, ultrasonication, electron beam irradiation, and X-ray irradiation).

Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.

Abstract: The present invention provides an implant capable of being cellularized in treatment of an injured organ or tissue in organisms. The present inventors found that a biocompatible implant comprising a biological molecule and a support is capable of being cellularized. The implant can be used instead of conventional implants which essentially comprise cells. The present invention provides a biocompatible implant comprising A) a biological molecule and B) a support. The present invention also provides A) a first layer having a rough surface, B) a rough surface; B) a second layer having a strength which allows the support to resist in vivo shock. The first layer is attached to the second layer via at least one point.

Abstract: The present invention provides introduction of NF-?B decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-?B decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor ?, interleukin 1? and intracellular adhesion molecule 1 messenger RNAs. Terminal deoxynucleotidyl transferase-mediated deoxyuridine nick-end labeling staining and immunohistochemistry using microtubule-associated protein 2 demonstrated that transfected NF-?B decoy oligodeoxynucleotide significantly attenuated neuronal damage seven days after global brain ischemia. Therapeutic transfection of NF-?B decoy oligodeoxynucleotide during brain ischemia may be effective for attenuation of neuronal damage, suggesting a strategy for protecting the cerebrum from global ischemia.

Abstract: A method for injecting a liquid drug containing a biological material is provided, which comprises the step of injecting the liquid drug containing the biological material contained in an injector into a subject at a predetermined range of velocity.

Abstract: An objective of the present invention is to overcome a problem that there is an inverse relationship between the decellularization rate and the strength of tissue. This problem was solved by immersing tissue in a solution containing a non-micellar amphipathic molecule (e.g., a 1,2-epoxide polymer). Thus, the present invention provides decellularized tissue, in which the cell survival rate of the tissue is less than a level at which calcification or an immune reaction is elicited in an organism and the tissue damage rate of the tissue is suppressed to a level which permits clinical applications. Tissue prepared by the above-described treatment preferably retains a certain level of tissue strength. Further, the tissue of the present invention has an effect of performing cell replacement.

Abstract: A method of preserving a harvested organ, a harvested organ tissue or a part thereof for a long time, which comprises perfusing and/or immersing the harvested organ with a solution containing HGF having a temperature of 0 to 6° C., and which method is capable of maintaining harvested organs for transplantation in a high physiological state and preventing ischemia/reperfusion injury of the organs transplanted.

Abstract: The invention provides a method of treating or preventing ischemia reperfusion injury in a subject in need thereof comprising administering a cytokine production inhibitor to a subject.

Abstract: A method for injecting a liquid drug containing a biological material is provided, which comprises the step of injecting the liquid drug containing the biological material contained in an injector into a subject at a predetermined range of velocity.

Abstract: A solid state imaging device is disclosed which includes a solid state sensor for converting an external scene into electrical signals, an A/D converter for converting output signals from the solid state sensor into digital signals, a frame memory for storing offset signals of the solid state sensor, and an arithmetic unit for subtracting the offset signals stored in the frame memory from the digital signals of the A/D converter, the signals from the arithmetic unit being output through a D/A converter and a synchronization adding circuit. In the thus constituted solid state imaging device, a judgement as to the level of the offset signal from the frame memory is made. If this level is lower than a predetermined value, it is judged that there is a defective pixel. Interpolation is then effected with neighboring peripheral pixel signals in a spatial processor.

Abstract: A solid state imaging device is disclosed which includes a solid state sensor for converting an external scene into electrical signals, an A/D converter for converting output signals from the solid state sensor into digital signals, a frame memory for storing offset signals of the solid state sensor, and an arithmetic unit for subtracting the offset signals stored in the frame memory from the digital signals of the A/D converter. The signals from the arithmetic unit are output through a D/A converter and a synchronization adding circuit. In the thus constituted solid state imaging device, a judgement as to the level of the offset signal from the frame memory is made. If this level is outside a predetermined range, it is judged that there is a defective pixel. Interpolation is then effected with neighboring pixel signals in a spatial processor.